Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alprostadil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 known ✓ | P43116 | 4/20 | 1.00 |
| ▸ | PTGER1 known ✓ | P34995 | 1/20 | 0.73 |
| ▸ | PTGIR | P43119 | 9/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | PTGER4 | P35408 | 3/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | RARB | P10826 | 1/20 | 1.00 |
| ▸ | RARG | P13631 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alprostadil SCHEMBL12987687 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL11695818 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| SCHEMBL11864105 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| SCHEMBL23353047 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| SCHEMBL7742103 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL23353103 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL23352620 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| SCHEMBL23352905 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL22425786 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| SCHEMBL11863995 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | claimed |
| CN-119296764-A | Marker for detecting sensitivity of tumor radiotherapy and screening method and application thereof | 福建医科大学附属协和医院 | 2025-01-10 | — | — | CN | disclosed |
| CN-119165078-A | Combined marker for detecting tumor radiotherapy sensitivity and application thereof | 福建医科大学附属协和医院 | 2024-12-20 | — | — | CN | disclosed |
| US-20240226160-A9 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240131072-A1 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-04-25 | — | — | US | disclosed |
| EP-4291571-A2 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | SEATTLE CHILDREN’S HOSPITAL DBA SEATTLE CHILDREN’S RES INSTITUTE (US) | 2023-10-12 | — | — | US | disclosed |
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | SEATTLE CHILDREN'S HOSPITAL (US) | 2023-05-16 | — | — | US | disclosed |
| US-11623009-B2 | Bone fracture repair by targeting of agents that promote bone healing | PURDUE RESEARCH FOUNDATION (US) | 2023-04-11 | — | — | US | disclosed |
| CN-110099990-B | Perfume mixture | 西姆莱斯股份公司 | 2022-11-29 | — | — | CN | disclosed |
| EP-0725642-A1 | STABILIZED PROSTAGLANDIN E 1? | PHARMACIA & UPJOHN COMPANY (US) | 1996-08-14 | — | — | EP | disclosed |
| WO-1995011683-A1 | STABILIZED PROSTAGLANDIN E¿1? | THE UPJOHN COMPANY (US) | 1995-05-04 | — | — | WO | disclosed |
| EP-0459377-A2 | Use of E1 prostaglandin to cure male erectile inpotence | Reale, Alberto (IT) | 1991-12-04 | — | — | EP | disclosed |
| EP-0257859-B1 | NOVEL COMBINATION | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-10-16 | — | — | EP | disclosed |
| US-4839169-A | BLOOD CLOT REMOVAL AND INHIBITION | BURROUGHS WELLCOME CO. (US) | 1989-06-13 | — | — | US | disclosed |
| US-3987082-A | PROSTAGLANDIN INTERMEDIATE | MERCK & CO., INC. (US) | 1976-10-19 | — | — | US | disclosed |
| US-3965120-A | Prostaglandin E1 intermediate 3-carboxymethyl-4-methyl-2-1-carboxy-7-(loweralkoxy or aralkoxycarbonyl)-heptyl]-4-hydroxybutyric acid, γ-lactone, and processes of their preparation | MERCK & CO., INC. (US) | 1976-06-22 | — | — | US | disclosed |
| US-3953499-A | 8,12-Dialkyl-PGE, and PGF1.sub.α | THE UPJOHN COMPANY (US) | 1976-04-27 | — | — | US | disclosed |
| US-3950359-A | PROSTAGLANDINS AND METHODS OF MAKING SAME | MERCK & CO., INC. (US) | 1976-04-13 | — | — | US | disclosed |
| US-3939182-A | Prostaglandin E1 intermediate 6α-carboxy-5α(1-hydroxyethyl)-2-cyclohexene-1-heptanoic acid,γ-lactone, and lower alkyl or aralkyl esters thereof | MERCK & CO., INC. (US) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11623009-B2 | Bone fracture repair by targeting of agents that promote bone healing | CTSK, CTSG, MMP13 | PTGER2 1102/4885PTGER1 181/4885PTGIR 419/4885 |
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | PHOSPHO1, LCAT, CD47 | PTGER2 1421/4885PTGER1 1162/4885PTGIR 623/4885 |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | PHOSPHO1, LCAT, CD47 | PTGER2 1421/4885PTGER1 1162/4885PTGIR 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.